MY193080A - Crystalline forms - Google Patents

Crystalline forms

Info

Publication number
MY193080A
MY193080A MYPI2019001474A MYPI2019001474A MY193080A MY 193080 A MY193080 A MY 193080A MY PI2019001474 A MYPI2019001474 A MY PI2019001474A MY PI2019001474 A MYPI2019001474 A MY PI2019001474A MY 193080 A MY193080 A MY 193080A
Authority
MY
Malaysia
Prior art keywords
crystalline forms
pharmaceutical compositions
phosphono
pyrrolidin
propionyl
Prior art date
Application number
MYPI2019001474A
Other languages
English (en)
Inventor
Daniel Leuenberger
Stefan Reber
Raumer Markus Von
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of MY193080A publication Critical patent/MY193080A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MYPI2019001474A 2016-09-22 2017-09-21 Crystalline forms MY193080A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2016072562 2016-09-22
PCT/EP2017/073858 WO2018055016A1 (en) 2016-09-22 2017-09-21 Crystalline forms

Publications (1)

Publication Number Publication Date
MY193080A true MY193080A (en) 2022-09-26

Family

ID=59923448

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2019001474A MY193080A (en) 2016-09-22 2017-09-21 Crystalline forms

Country Status (27)

Country Link
US (4) US10730896B2 (enExample)
EP (2) EP3515924B1 (enExample)
JP (1) JP7097369B2 (enExample)
KR (1) KR102552795B1 (enExample)
CN (1) CN109715639B (enExample)
AU (1) AU2017331930B2 (enExample)
CA (1) CA3037794A1 (enExample)
CL (1) CL2019000728A1 (enExample)
CY (1) CY1125052T1 (enExample)
DK (1) DK3515924T3 (enExample)
EA (1) EA201990723A1 (enExample)
ES (1) ES2908572T3 (enExample)
HR (1) HRP20220234T1 (enExample)
HU (1) HUE057772T2 (enExample)
IL (1) IL265445B2 (enExample)
LT (1) LT3515924T (enExample)
MA (1) MA46266B1 (enExample)
MX (1) MX381590B (enExample)
MY (1) MY193080A (enExample)
PH (1) PH12019500567B1 (enExample)
PL (1) PL3515924T3 (enExample)
PT (1) PT3515924T (enExample)
RS (1) RS62946B1 (enExample)
SI (1) SI3515924T1 (enExample)
TW (1) TWI752086B (enExample)
UA (1) UA124073C2 (enExample)
WO (1) WO2018055016A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3515924T3 (da) 2016-09-22 2022-03-21 Idorsia Pharmaceuticals Ltd Krystallinske former
SG11201908128YA (en) 2017-03-15 2019-10-30 Idorsia Pharmaceuticals Ltd Subcutaneous administration of a p2y12 receptor antagonist
RS67649B1 (sr) 2020-07-15 2026-02-27 Viatris Asia Pacific Pte Ltd Vodena farmaceutska kompozicija koja sadrži antagonistu p2y12 receptora
IL309948A (en) * 2021-07-13 2024-03-01 Idorsia Pharmaceuticals Ltd A process for the synthesis of 4-((R)-2-{[6-((S)-3-methoxy-pyrrolidin-1-yl)-2-phenyl-pyrimidin-4-carbonyl]-amino}-3-phosphono- Propionyl)-piperazine-1-carboxylic acid butyl ester

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5373586A (en) 1976-12-09 1978-06-30 Mitsubishi Chem Ind Ltd New penicillin derivatives
CA2020437A1 (en) 1989-07-05 1991-01-06 Yoshihide Fuse Cinnamamide derivative
ES2248084T3 (es) 1999-06-14 2006-03-16 Eli Lilly And Company Inhibidores de serinproteasa.
US6861424B2 (en) 2001-06-06 2005-03-01 Schering Aktiengesellschaft Platelet adenosine diphosphate receptor antagonists
EA200500899A1 (ru) 2002-12-11 2006-02-24 Шеринг Акциенгезельшафт Антагонисты аденозиндифосфатного рецептора тромбоцитов
US7253153B2 (en) 2003-04-09 2007-08-07 Wyeth Derivatives of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and methods of use thereof
TW200640877A (en) 2005-04-28 2006-12-01 Actelion Pharmaceuticals Ltd Pyrimidine derivatives
TWI382976B (zh) 2005-10-21 2013-01-21 Actelion Pharmaceuticals Ltd 作為抗瘧疾劑之新穎哌
CL2007002920A1 (es) 2006-10-13 2008-06-06 Actelion Pharmaceuticals Ltd Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos.
AR063518A1 (es) 2006-10-25 2009-01-28 Actelion Pharmaceuticals Ltd Derivados 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y su uso para tratar y/o prevenir enfermedades vasculares perifericas viscerales, hepaticas y renales, enfermedades cardiovasculares y enfermedades cerebrovasculares asociados con la agregacion de plaquetas, incluyendo trombosis
JP4785881B2 (ja) 2007-02-27 2011-10-05 大塚製薬株式会社 医薬
WO2008128647A1 (en) 2007-04-23 2008-10-30 Sanofi-Aventis Quinoline-carboxamide derivatives as p2y12 antagonists
JP4729133B2 (ja) 2007-11-29 2011-07-20 アクテリオン ファーマシューティカルズ リミテッド ホスホン酸誘導体及びp2y12受容体拮抗剤としてのそれらの使用
EP2238127B1 (en) 2007-12-26 2012-08-15 Sanofi Pyrazole-carboxamide derivatives as p2y12 antagonists
WO2009080226A2 (en) 2007-12-26 2009-07-02 Sanofis-Aventis Heterocyclic pyrazole-carboxamides as p2y12 antagonists
AR071652A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2- fenil-piridina substituidos
AR071653A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2-fenil-4-ciclopropil-pirimidina
CA2756542C (en) 2009-04-08 2017-08-22 Actelion Pharmaceuticals Ltd 6-(3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidines
CA2756654C (en) 2009-04-22 2017-08-22 Actelion Pharmaceuticals Ltd Thiazole derivatives and their use as p2y12 receptor antagonists
DK3515924T3 (da) 2016-09-22 2022-03-21 Idorsia Pharmaceuticals Ltd Krystallinske former
SG11201908128YA (en) 2017-03-15 2019-10-30 Idorsia Pharmaceuticals Ltd Subcutaneous administration of a p2y12 receptor antagonist
RS67649B1 (sr) 2020-07-15 2026-02-27 Viatris Asia Pacific Pte Ltd Vodena farmaceutska kompozicija koja sadrži antagonistu p2y12 receptora

Also Published As

Publication number Publication date
PH12019500567A1 (en) 2019-11-18
US11365209B2 (en) 2022-06-21
IL265445A (en) 2019-05-30
MA46266A (fr) 2019-07-31
JP7097369B2 (ja) 2022-07-07
BR112019004845A2 (pt) 2019-06-04
CL2019000728A1 (es) 2019-07-05
EP3515924B1 (en) 2021-12-15
JP2019529553A (ja) 2019-10-17
US20200017534A1 (en) 2020-01-16
KR102552795B1 (ko) 2023-07-06
PH12019500567B1 (en) 2024-01-31
US12227532B2 (en) 2025-02-18
TW201813965A (zh) 2018-04-16
US20210009614A1 (en) 2021-01-14
AU2017331930A1 (en) 2019-03-07
HRP20220234T1 (hr) 2022-05-13
MA46266B1 (fr) 2022-02-28
IL265445B1 (en) 2024-01-01
LT3515924T (lt) 2022-03-10
ES2908572T3 (es) 2022-05-03
KR20190052704A (ko) 2019-05-16
MX2019003093A (es) 2019-07-18
EP3981774A1 (en) 2022-04-13
DK3515924T3 (da) 2022-03-21
IL265445B2 (en) 2024-05-01
EA201990723A1 (ru) 2019-10-31
CA3037794A1 (en) 2018-03-29
US20220275011A1 (en) 2022-09-01
AU2017331930B2 (en) 2021-07-15
CN109715639B (zh) 2022-04-19
TWI752086B (zh) 2022-01-11
US20250163086A1 (en) 2025-05-22
EP3515924A1 (en) 2019-07-31
CN109715639A (zh) 2019-05-03
CY1125052T1 (el) 2024-02-16
US10730896B2 (en) 2020-08-04
PL3515924T3 (pl) 2022-04-11
RS62946B1 (sr) 2022-03-31
WO2018055016A1 (en) 2018-03-29
MX381590B (es) 2025-03-12
SI3515924T1 (sl) 2022-04-29
PT3515924T (pt) 2022-03-11
UA124073C2 (uk) 2021-07-14
HUE057772T2 (hu) 2022-06-28
NZ750772A (en) 2023-10-27

Similar Documents

Publication Publication Date Title
PH12020551089A1 (en) Pyrrolopyrimidine compounds used as tlr7 agonist
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
EA033544B1 (ru) Производные пиридона в качестве ингибиторов киназы, реаранжированной во время трансфекции (ret)
WO2016105564A8 (en) Quinazoline derivatives used to treat hiv
HK1255102A1 (zh) 杂环化合物及其应用
NZ721298A (en) Pharmaceutical compositions comprising azd9291
MX2017014035A (es) Formas solidas novedosas.
WO2014155300A3 (en) Substitued pyrimidine amine derivatives as tak-1 inhibitors
MX2021011906A (es) Composiciones de liberacion retardada de linaclotida.
NZ725399A (en) Macrocylic pyrimidine derivatives
MX2016012994A (es) Derivados de piridina macrociclicos.
CY1125052T1 (el) Κρυσταλλικες μορφες
MX386902B (es) Metodos para el tratamiento de trastornos cardiovasculares.
MX2017008074A (es) DERIVADOS DE IMIDAZOPIRIDAZINA COMO INHIBIDORES DE FOSFOINOSITIDA-3-QUINASAS BETA (PI3Kß).
WO2016006974A3 (en) Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
WO2016006975A3 (en) Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof
WO2016197042A8 (en) Modified or targeted release formulations of linaclotide
MX2017008076A (es) DERIVADOS DE IMIDAZOPIRIDAZINA ENLAZADOS A HETEROCICLILO COMO INHIBIDORES DE PI3Kß.
WO2016165205A8 (zh) 一种新型的bcr-abl激酶抑制剂
PH12018500505A1 (en) Crystalline forms
WO2017029642A3 (en) Novel polymorphs of dolutegravir and salts thereof
TH1901001696A (th) รูปแบบที่เป็นผลึก
GR1008380B (el) Φαρμακευτικο σκευασμα περιεχον ενα αντιικο παραγοντα και μεθοδος για την παρασκευη αυτου
IN2014KO00191A (enExample)